I n healthcare, value has been defined as the condition-specific medical outcome per dollar spent [7] . In terms of quality of life, THA has proven to be one of the most valuable and cost-effective procedures in modern medicine [5, 6] . We know that patients who undergo THA have a higher life expectancy compared to the general population [4, 8, 9] . Why? In part because patients who undergo THA are medically prescreened for elective surgery [8] , resulting in the population of patients undergoing hip arthroplasty generally being healthier than others in their age group. Additionally, though, patients with THAs can improve cardiovascular fitness and functional status after surgery [8] , potentially mitigating other risk factors for mortality over the long-term [1] . The latter, in particular, increases the value of the THA procedure, which is important because in the era of bundled payments and value-drive healthcare, the merit (value) of THA is coming under more and more scrutiny. Nevertheless, the benefits of THA must always be considered against the outcome of not undergoing an elective THA.
The current study by Kremers and colleagues examined life expectancy after revision THA, where the improvement in life expectancy is not as well characterized as it is among patients undergoing elective primary THA. To my knowledge, this paper is the first longer-term study that reports patient longevity after revision THA according to indication (loosening, wear, instability, infection, and fracture) and year of surgery.
Where Do We Need To Go?
Life expectancy is an important consideration during the presurgical decision-making process [2] , even for certain indications for revision THA where the decision-making is not entirely elective (such as infection, fracture, or recurrent dislocation). For surgeons, life expectancy may have substantial influence on treatment options. For patients, an understanding of this prognostic information can support shared decision-making.
The current study improves our understanding of patient survivorship after revision THA. The authors note the challenges of categorizing the results according to indications, medical conditions, ethnicity, race, and socioeconomic status. Finally, patient longevity is only one of many outcomes to be scrutinized in a value-driven healthcare system. Measuring, reporting, and comparing outcomes are important steps in determining value [7] . This process includes revision THA as well.
While the study adds to our knowledge, questions remain: Does patient survivorship change over time? How do surgeons factor patient comorbidities into their decisions about whether to perform revision THA for various indications, and how do these comorbidities differentially influence life expectancy? How feasible is it to modify some of these factors prior to surgery? How does surgeon volume or hospital volume impact longevity?
How Do We Get There?
We can answer these questions by performing detailed and retrospective analyses of large institutional, multicenter, insurance, or national databases and registries of revision THAs. Because certain indications for revision are less common than others, reviewing a relatively larger group of revision THAs might identify important variances in common patient characteristics. Reviews from smaller arthroplasty centers with smaller cohorts may be insufficient to determine accurately any potential differences in patient longevity based on age, sex, medical diagnoses, comorbidities, and surgical indications. This information will be important both to the patient and the surgeon during the decision-making process. Knowledge of life expectancy is important to hospital systems and third-party payers as these groups are particularly interested in cost-efficient results. Indeed, primary THA is no longer simply defined and evaluated in terms of pain relief, functional outcome, and prosthetic survival. These results are now expressed within the context of accepted dictums like "cost containment," "healthcare value," and "healthcare resources." A similar trend in the evaluation of the results of revision THA, including patient longevity and survival, is not far behind.
